# ASTRUM-002 (NCT03952403)

> A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

- Drugs tested: serplulimab plus bevacizumab; serplulimab
- Indication: first-line advanced non-squamous NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03952403
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Shanghai Henlius Biotech
- Conditions: Carcinoma; Non-Small-Cell Lung
- Interventions: HLX10, an engineered anti-PD-1 antibody; HLX04, a bevacizumab biosimilar; Carboplatin; Pemetrexed
- Enrollment: 643
- Primary outcome: Part 1 Safety and tolerability of study treatment
- Primary outcome: Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

## Indexed commentary on ASTRUM-002 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4
- Podcasts: 1

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=astrum-002-nct03952403